Mandatory tax sale: Taysha (TSHA) CFO sells 1,655 common shares

Rhea-AI Filing Summary

Taysha Gene Therapies Chief Financial Officer Kamran Alam reported a small insider sale tied to taxes. On February 4, 2026, he sold 1,655 shares of common stock at $4.52 per share. The footnote explains this was a mandatory sell-to-cover transaction to pay income taxes from restricted stock unit vesting. After the sale, Alam directly held 1,442,131 shares of Taysha Gene Therapies common stock.

Insider Trade Summary

Net Seller: 1,655 shares ($7,481)

Net Sell 1 txn

Insider Alam Kamran

Role CHIEF FINANCIAL OFFICER

Sold 1,655 shs ($7K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,655	$4.52	$7K

Holdings After Transaction: Common Stock — 1,442,131 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Alam Kamran

(Last) (First) (Middle)

C/O TAYSHA GENE THERAPIES, INC.

3000 PEGASUS PARK DRIVE, STE 1430

(Street)

DALLAS TX 75247

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Taysha Gene Therapies, Inc. [ TSHA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/04/2026		S		1,655(1)	D	$4.52	1,442,131	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.

	/s/ Kamran Alam	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Taysha Gene Therapies (TSHA) CFO report?

Taysha Gene Therapies CFO Kamran Alam reported a small mandatory share sale. On February 4, 2026, he sold 1,655 shares of common stock at $4.52 per share, as disclosed in a Form 4 insider trading report filed under Section 16 rules.

How many Taysha Gene Therapies (TSHA) shares did the CFO sell and at what price?

Kamran Alam sold 1,655 TSHA common shares at $4.52 each. The Form 4 shows a single transaction dated February 4, 2026, with the sale coded as an "S" transaction, indicating a disposition of non-derivative common stock on the open market.

Why did Taysha Gene Therapies (TSHA) CFO Kamran Alam sell shares in this Form 4?

The sale was to cover income taxes from restricted stock unit vesting. The footnote states the transaction was a mandatory sell-to-cover arrangement, used solely to satisfy tax liabilities incurred when restricted stock unit awards vested.

How many Taysha Gene Therapies (TSHA) shares does the CFO own after the reported sale?

After the transaction, Kamran Alam beneficially owned 1,442,131 TSHA shares. The Form 4 shows this as his direct ownership position following the 1,655-share sale, indicating he continues to hold a substantial amount of the company’s common stock.

Is the TSHA CFO’s Form 4 transaction a routine sell-to-cover tax sale?

Yes, the filing describes it as a mandatory sell-to-cover transaction. According to the footnote, the 1,655 shares were sold solely to meet income tax obligations triggered by the vesting of restricted stock unit awards, rather than a discretionary portfolio decision.